{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:49:05Z","timestamp":1790995745344,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Cardiovascular\u2013kidney\u2013metabolic (CKM) syndrome defines a pathophysiological continuum driven by reciprocal dysfunction across the cardiovascular, renal and metabolic systems. Although sodium\u2013glucose co-transporter 2 inhibitors (SGLT2i) provide consistent, organ-protective benefits across this spectrum, clinical implementation remains suboptimal. This expert opinion, developed by a multidisciplinary Italian board, aims to translate current evidence and guideline recommendations into practical, integrated strategies for the early and effective implementation of SGLT2i in patients at risk of or affected by CKM syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The panel reviewed the latest clinical trial data, international guidelines, and real-world evidence to identify implementation gaps and propose actionable solutions across diabetology, cardiology, and nephrology. Clinical recommendations were formulated via informal multidisciplinary roundtable discussions. Despite strong evidence and broad guideline endorsement, SGLT2i remain underutilized due to fragmented care, therapeutic inertia, and misconceptions regarding safety. To address these barriers, we advocate for early risk-based screening, simplified treatment algorithms, cross-specialty collaboration, and educational efforts to empower both clinicians and patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Shifting from reactive to proactive CKM management requires an integrated care model aligning specialties around early, organ-protective interventions. SGLT2i should be recognized as foundational, disease-modifying therapy, supported by multidisciplinary coordination, clear clinical algorithms, and patient-centered communication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag020","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:48:02Z","timestamp":1775735282000},"page":"209-221","source":"Crossref","is-referenced-by-count":5,"title":["Implementing sodium\u2013glucose co-transporter 2 inhibitors in cardiovascular\u2013kidney\u2013metabolic syndrome: a multidisciplinary expert perspective"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1177-0516","authenticated-orcid":false,"given":"Angelo","family":"Avogaro","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Diabetology, Veneto Institute of Molecular Medicine , Via Giuseppe Orus 2, 35129 Padua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5509-8867","authenticated-orcid":false,"given":"Mauro","family":"Gori","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Department, Papa Giovanni XXIII Hospital , 24127 Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1213-2177","authenticated-orcid":false,"given":"Giuseppe","family":"Grandaliano","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore , 00168 Rome ,","place":["Italy"]},{"name":"Nephrology, Dialysis and Transplantation Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS , 00168 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9613-5062","authenticated-orcid":false,"given":"Massimo","family":"Iacoviello","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Foggia , 71122 Foggia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0420-4468","authenticated-orcid":false,"given":"Roberto","family":"Trevisan","sequence":"additional","affiliation":[{"name":"Endocrinology and Diabetes Unit, Azienda Ospedaliera Papa Giovanni XXIII , 24127 Bergamo ,","place":["Italy"]},{"name":"Department of Medicine and Surgery, University of Milano Bicocca , 20126 Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"2026051910562396000_pvag020-B1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082833","article-title":"Cardiovascular-kidney-metabolic syndrome: a new paradigm in clinical medicine or going back to basics?","volume":"14","author":"Mutruc","year":"2025","journal-title":"J Clin Med"},{"key":"2026051910562396000_pvag020-B2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1583702","article-title":"A holistic approach to managing cardio-kidney metabolic syndrome: insights and recommendations from the Italian perspective","volume":"12","author":"Iacoviello","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"2026051910562396000_pvag020-B3","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2026051910562396000_pvag020-B4","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/ndt\/gfae086","article-title":"Refocusing cardio-renal problems: the cardiovascular-kidney-metabolic syndrome and the chronic cardiovascular-kidney disorder","volume":"39","author":"Zoccali","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026051910562396000_pvag020-B5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pcad.2024.10.012","article-title":"Cardiovascular-kidney-metabolic syndrome\u2014an integrative review","volume":"87","author":"Kittelson","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"2026051910562396000_pvag020-B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155931","article-title":"DCRM 2.0: multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","volume":"159","author":"Handelsman","year":"2024","journal-title":"Metabolism"},{"key":"2026051910562396000_pvag020-B7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-8587(20)30344-2","article-title":"Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial","volume":"8","author":"McGuire","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026051910562396000_pvag020-B8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026051910562396000_pvag020-B9","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in patients with heart failure and preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026051910562396000_pvag020-B10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13081924","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists in cardiovascular-kidney-metabolic syndrome","volume":"13","author":"Gajjar","year":"2025","journal-title":"Biomedicines"},{"key":"2026051910562396000_pvag020-B11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/antiox14060701","article-title":"Antioxidant effects of SGLT2 inhibitors on cardiovascular-kidney-metabolic (CKM) syndrome","volume":"14","author":"Guerrero-Mauvecin","year":"2025","journal-title":"Antioxidants (Basel)"},{"key":"2026051910562396000_pvag020-B12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ccl.2024.12.002","article-title":"Sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular kidney metabolic syndrome","volume":"43","author":"Lo","year":"2025","journal-title":"Cardiol Clin"},{"key":"2026051910562396000_pvag020-B13","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-024-01550-5","article-title":"SGLT2 inhibitors\u2014the new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review","volume":"15","author":"Seidu","year":"2024","journal-title":"Diabetes Ther"},{"key":"2026051910562396000_pvag020-B14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026051910562396000_pvag020-B15","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","article-title":"2. Classification and diagnosis of diabetes: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2026051910562396000_pvag020-B16","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026051910562396000_pvag020-B17","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026051910562396000_pvag020-B18","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026051910562396000_pvag020-B19","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026051910562396000_pvag020-B20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ehf2.14857","article-title":"2024 update in heart failure","volume":"12","author":"Beghini","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026051910562396000_pvag020-B21","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026051910562396000_pvag020-B22","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"2026051910562396000_pvag020-B23","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2026051910562396000_pvag020-B24","author":"Associazione Medici Diabetologi (AMD)"},{"key":"2026051910562396000_pvag020-B25","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.cardfail.2025.02.019","article-title":"Medical treatments in patients with ambulatory heart failure: first data from the BRING-UP-3 heart failure study","volume":"31","author":"Oliva","year":"2025","journal-title":"J Card Fail"},{"key":"2026051910562396000_pvag020-B26","doi-asserted-by":"publisher","DOI":"10.1177\/1479164120973676","article-title":"Diabetes, metformin and glucose lowering therapies after myocardial infarction: insights from the SWEDEHEART registry","volume":"17","author":"Ritsinger","year":"2020","journal-title":"Diab Vasc Dis Res"},{"key":"2026051910562396000_pvag020-B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101032","article-title":"SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART","volume":"45","author":"Ros\u00e9n","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026051910562396000_pvag020-B28","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/ejhf.3267","article-title":"Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: first data from the TITRATE-HF study","volume":"26","author":"Malgie","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026051910562396000_pvag020-B29","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1111\/dom.15194","article-title":"Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD registry, 2019\u20132020","volume":"25","author":"Nicholas","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026051910562396000_pvag020-B30","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae169","article-title":"Assessment of SGLT2 inhibitors\u2019 safety and discontinuation causes in patients with advanced chronic kidney disease: insights from a real-world data analysis","volume":"17","author":"Perrin","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026051910562396000_pvag020-B31","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1714\/4181.41696","article-title":"Empagliflozin: attuali indicazioni e aspetti pratici di utilizzo [Empagliflozin: current indications and aspects for daily clinical practice]","volume":"24","author":"Iacoviello","year":"2023","journal-title":"G Ital Cardiol (Rome)"},{"key":"2026051910562396000_pvag020-B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurheartj\/ehaf788","article-title":"Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients","volume":"00","author":"Wu","year":"2025","journal-title":"Eur Heart J"},{"key":"2026051910562396000_pvag020-B33","author":"National Institute for Health and Care Excellence"},{"key":"2026051910562396000_pvag020-B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100847","article-title":"Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk","volume":"38","author":"Fadini","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026051910562396000_pvag020-B35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/eurheartj\/ehaf675","article-title":"Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure","volume":"47","author":"Docherty","year":"2025","journal-title":"Eur Heart J"},{"key":"2026051910562396000_pvag020-B36","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/eurheartj\/ehaf681","article-title":"Guideline-recommended preventive management in metabolic and renal disease: a paradigm shift for all healthcare professionals to maintain \u2018normal\u2019 cardiac function","volume":"47","author":"Bruno","year":"2026","journal-title":"Eur Heart J"},{"key":"2026051910562396000_pvag020-B37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026051910562396000_pvag020-B38","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1111\/dom.70445","article-title":"The importance of treatment sequencing with SGLT2 inhibitors and GLP-1 receptor agonists combination for kidney function preservation in type 2 diabetes","volume":"28","author":"Morieri","year":"2026","journal-title":"Diabetes Obes Metab"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag020\/68030922\/pvag020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/3\/209\/68030922\/pvag020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/3\/209\/68030922\/pvag020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:56:30Z","timestamp":1779202590000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/3\/209\/8651384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4,10]]},"published-print":{"date-parts":[[2026,5,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag020","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,10]]}}}